Investors Eye Bispecific Antibodies as Clinical Data Drives Decisions

In an era where conventional monoclonal antibodies face patent expiries and mounting clinical limitations, the pharmaceutical industry is increasingly betting on bispecific antibodies — engineered proteins designed to engage two targets at once — as the next frontier in treatment. These dual-target agents aim to sharpen precision, reduce side effects, and expand the therapeutic reach across oncology, autoimmune diseases and ophthalmology.

“We think it’s the next generation antibody treatment,” said Dr. Jo Hsu, project manager for business development at AP Biosciences. “They’re designed to be more precise, more efficient and, in many cases, safer with lower risk.” Her comments reflect broader industry momentum, where deal volumes and values for bispecific assets have surged compared with recent years.

Tumor Targeting: The Biggest Prize

Bispecific antibodies — as Hsu explained — are conceptually simple: “One antibody has two targets.” One arm might latch onto a tumor-associated antigen, while the other engages either another tumor marker or an immune cell such as a T-cell. The goal is to drive more effective tumor recognition and clearance while limiting nonspecific immune activation.

That dual-target logic positions bispecifics as potential successors to blockbuster immunotherapies like Keytruda (pembrolizumab), which revolutionized cancer care but still leaves many patients unresponsive. By simultaneously hitting checkpoints and tumor angiogenesis pathways, industry players are trying to overcome Keytruda’s limitations and expand clinical efficacy.

Recent major licensing deals underscore this trend:

• Pfizer’s exclusive licensing agreement with 3SBio for a bispecific antibody targeting PD-1 and VEGF, SSGJ-707, involves $1.25 billion upfront and up to $4.8 billion in milestone payments — a deal that could total more than $6 billion if all metrics are met. The asset is in advanced clinical trials for non-small cell lung cancer, colorectal and gynecologic tumors.
• BioNTech and Bristol Myers Squibb (BMS) signed a global co-development agreement for BNT327, a PD-L1×VEGF-A bispecific, with combined upfront and milestone potential north of $11 billion. The collaboration aims to advance the asset across multiple solid tumor types and is positioned as next-gen backbone immunotherapy.

Hsu noted that these kinds of collaborations mirror industry recognition of the unmet need in oncology. “Solid tumors still have a huge amount of unmet need because each cancer type has its own character,” she said, highlighting inherent complexity in solid tumor biology. “If we can alleviate the immunosuppressive tumor microenvironment and reduce immune evasion, I think the efficiency can increase.”

Beyond Tumors: Hematology, Autoimmunity & Eyes

While solid tumors represent the largest market opportunity, Hsu pointed out that “there are other areas where bispecifics are gaining traction.”

Hematologic malignancies were the first therapeutic class to see approved bispecifics, especially CD3-based T-cell engagers. Yet the space continues to evolve with next-generation formats and licensing activity, such as recent substantial partnerships in multiple myeloma focused on trispecific T-cell engagers.

In autoimmune diseases, bispecific constructs are being designed to modulate the immune response more fundamentally than conventional therapies. A growing number of deals target complex immune dysregulation, reflecting the need for better disease-modifying agents.

Perhaps most striking is ophthalmology, where bispecific therapies are reshaping treatment burdens for chronic eye disease. Roche’s Vabysmo, a bispecific targeting VEGF and angiopoietin-2, achieved over $4 billion in sales in 2024, driven by its ability to extend time between intravitreal injections compared with standard anti-VEGF monotherapies — a major quality-of-life advantage for patients. (Comparable annual sales growth of ~62% year-over-year was reported.)

Hsu highlighted this opportunity: “Unlike traditional monthly eye injections, a bispecific antibody allows many patients to extend dosing intervals up to every four months,” an incremental improvement with real patient impact.

Technology Gaps and the Next Innovation Wave

Despite the clinical promise and surging deal activity, Hsu stressed that scientific and delivery challenges remain.

Tissue Penetration: Large antibody molecules inherently struggle to penetrate dense solid tumors, limiting therapeutic reach. Industry players are exploring solutions, including enzymatic enhancement and alternative formulations. For example, platforms such as Halozyme’s ENHANZE® — an enzyme-based technology — have been licensed by multiple partners (including BMS for subcutaneous formulations of PD-1 inhibitors like Opdivo) to improve distribution and reduce administration burden.

Blood-Brain Barrier: Crossing the blood-brain barrier (BBB) remains a key frontier. Hsu drew attention to pipeline technologies such as engineered shuttles that ferry large molecules across the BBB, which could open bispecific utility in central nervous system disease — a historically elusive target for biologics.

Modality Shift: Cold Tumors and Innate Immunity: Hsu also referenced evolving research into “cold tumors,” which are resistant to immune infiltration, and novel targets such as innate immune activators that might unlock new therapeutic paths. This reflects a broader industry pivot toward precision immunomodulation and microenvironment targeting.

Market Outlook: Momentum With Clear Next Gates

By the end of the conversation, one point emerged clearly: interest in bispecific antibodies is accelerating, but progress remains tethered to data. Asked whether the market — in Taiwan and globally — can sustain current enthusiasm, Hsu was measured. “We still have to wait until Phase 2 data to have something solid and concrete,” she said, highlighting how clinical proof continues to define credibility and valuation.

This perspective aligns with broader investor behavior. While deals are rising, capital increasingly concentrates on assets that have passed early safety validation and shown differentiated efficacy. For bispecific programs, Phase 2 readouts now serve as a critical inflection point: confirming biological rationale, de-risking safety, and shaping regulatory and partnering strategies.

For observers, the pattern is familiar: early discovery fuels platform narratives, Phase 1 tests feasibility, and Phase 2 determines whether a bispecific can move from experimental promise to development priority — the stage when late-stage design, commercial positioning, and lifecycle planning come into focus.

What to Watch Next

For industry newcomers and professionals alike, the bispecific antibody landscape blends scientific innovation with strategic dealmaking, where clinical proof, patient benefit, and commercial incentives intersect.

Looking ahead, several milestones will likely define the next stage of the bispecific antibody cycle:

• Clinical validation over concept: Programs that demonstrate clear advantages over monoclonals — whether through response durability, reduced dosing frequency, or expanded patient eligibility — will increasingly separate from the field.
• Delivery and formulation breakthroughs: Advances in tissue penetration, BBB crossing, and half-life extension will move from enabling technologies to competitive differentiators.
• Indication expansion beyond crowded markets: While solid tumors remain the largest opportunity, ophthalmology, autoimmune disease, and CNS indications may offer faster paths to dominance in more concentrated markets.
• Partnership timing discipline: Large pharma interest is unlikely to slow, but collaboration decisions will continue to hinge on data maturity rather than platform breadth alone.

Rather than a single inflection point, bispecifics are entering a sequenced development phase, where progress is measured in gated steps. Over the next 12 to 24 months, the focus will be less on hype and more on programs that cross the thresholds turning scientific ambition into durable clinical and commercial relevance.

As Hsu put it, the direction is clear, but the pace is set by evidence. “Everyone is excited about bispecific antibodies,” she said. “But at the end of the day, it still comes back to the data — you need solid Phase 2 results to really move to the next step.”

In that sense, bispecifics are less a sudden disruption than a measured evolution. Their dual targeting and mechanistic flexibility position them to reshape treatment across oncology, autoimmunity, and ophthalmology — but only if they consistently solve delivery challenges, demonstrate meaningful clinical benefit, and withstand scrutiny in selective global markets.

The bispecific antibody landscape is evolving in sequenced steps, with clinical proof, delivery innovation, and strategic partnerships shaping the next wave of therapeutic breakthroughs. Image: GeneOnline

Author

Bernice Lottering